

Resource Summary Report

Generated by [NIF](#) on Sep 19, 2026

J82

RRID:CVCL_0359

Type: Cell Line

Proper Citation

RRID:CVCL_0359

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0359

Proper Citation: RRID:CVCL_0359

Description: Cell line J82 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Bladder carcinoma

Defining Citation: [PMID:77569](#), [PMID:571047](#), [PMID:687519](#), [PMID:833871](#), [PMID:864752](#), [PMID:870558](#), [PMID:2594029](#), [PMID:3413074](#), [PMID:3518877](#), [PMID:3708594](#), [PMID:4057431](#), [PMID:6220172](#), [PMID:6244232](#), [PMID:6582512](#), [PMID:6823318](#), [PMID:7787250](#), [PMID:8077054](#), [PMID:9137463](#), [PMID:9850064](#), [PMID:11416159](#), [PMID:11921286](#), [PMID:12127398](#), [PMID:14762065](#), [PMID:15846775](#), [PMID:16885334](#), [PMID:20164919](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23401075](#), [PMID:24035680](#), [PMID:24367658](#), [PMID:25997541](#), [PMID:26589293](#), [PMID:27270441](#), [PMID:27397505](#), [PMID:29732388](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31978347](#), [PMID:35839778](#)

Comments: Population: Caucasian; Swedish., Part of: UBC-40 urothelial bladder cancer cell line index., Part of: PTEN genetic alteration cell panel (ATCC TCP-1030)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: BLA-40 bladder carcinoma cell line panel.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: J82

Synonyms: J-82, J 82, J82COT, J82 COT, J82 CO'T, J82/WT

Cross References: BTO:BTO_0001671, CLO:CLO_0007006, EFO:EFO_0002210, MCCL:MCC:0000253, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:HTB-1, BioSample:SAMN03471085, BioSample:SAMN10987788, cancercellines:CVCL_0359, CCRID:1101HUM-PUMC000346, CCRID:3101HUMTCHu218, CCRID:4201HUM-CCTCC00225, CCTCC:GDC0225, Cell_Model_Passport:SIDM00693, ChEMBL-Cells:ChEMBL3308508, ChEMBL-Targets:ChEMBL614586, CLS:305055, Cosmic:753566, Cosmic:755399, Cosmic:760474, Cosmic:808517, Cosmic:809378, Cosmic:845571, Cosmic:846276, Cosmic:867838, Cosmic:943731, Cosmic:1016887, Cosmic:1046674, Cosmic:1093984, Cosmic:1175827, Cosmic:1285119, Cosmic:1285996, Cosmic:1302362, Cosmic:1927308, Cosmic:1995459, Cosmic:2050445, Cosmic:2057450, Cosmic:2444229, Cosmic:2686097, Cosmic:2700997, Cosmic-CLP:753566, DepMap:ACH-000396, EGA:EGAS00001000978, GDSC:753566, GEO:GSM136231, GEO:GSM492491, GEO:GSM827204, GEO:GSM887167, GEO:GSM888239, GEO:GSM1374575, GEO:GSM1574579, GEO:GSM1669946, IARC_TP53:3721, IARC_TP53:21416, IGRhCellID:J82, KCB:KCB 2014052YJ, KCLB:30001, LiGeA:CCLE_551, LINCS_LDP:LCL-1714, PharmacDB:J82_675_2019, PRIDE:PXD030304, PRIDE:PXD032049, Progenetix:CVCL_0359, PubChem_Cell_line:CVCL_0359, Wikidata:Q54898490

ID: CVCL_0359

Record Creation Time: 20220427T220644+0000

Record Last Update: 20260913T004619+0000

Ratings and Alerts

No rating or validation information has been found for J82.

No alerts have been found for J82.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 38 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Schmitz J, et al. (2026) Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107. Molecular oncology, 20(3), 779.

Chen Z, et al. (2026) An AI-Driven Multi-Omics Framework Identifies CASP8 as a Clinically Actionable Pyroptosis Biomarker in Bladder Cancer. BioFactors (Oxford, England), 52(4), e70130.

Ying X, et al. (2026) m5C-Modified tRF3b-CysGCA-23 Suppresses Bladder Cancer Malignancy by Repressing H3K18 Lactylation via Stabilizing RBM4. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(26), e22294.

Yu K, et al. (2026) Lactylation enhances YTHDF3 stability to promote cisplatin resistance via m6A-dependent KDM6B decay in bladder cancer. *Cancer letters*, 642, 218282.

Shi Y, et al. (2026) piR-43452 suppresses bladder cancer progression and enhances gemcitabine sensitivity via GTSF1/PIWIL4-mediated LRP1 mRNA destabilization. *Translational oncology*, 63, 102626.

Stuckey JI, et al. (2026) Covalent PPAR γ inverse agonism by FX-909 reveals mechanistic insights into therapeutic targeting of PPAR γ /RXR γ -activated urothelial carcinoma. *Cell chemical biology*, 33(6), 837.

Kotollosi R, et al. (2026) ZW4864-mediated inhibition of the β -catenin/BCL9/BCL9L complex reveals therapeutic potential in bladder cancer. *Molecular oncology*.

Wu J, et al. (2026) O-GlcNAcylated TAP1 Impairs Antigen Presentation and Promotes Immune Evasion in Bladder Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 13(37), e19955.

Kabus M, et al. (2026) Combining 5-ALA-PDT with berbamine as an in vitro multimodal therapy approach against bladder cancer cells. *Scientific reports*, 16(1).

Chen C, et al. (2025) TERC Stimulates Fatty Acid Metabolism to Promote Bladder Cancer Progression. *Cancer research*, 85(19), 3689.

Li Y, et al. (2025) Comprehensive pan-cancer single-cell analysis reveals glycolysis-related signatures as predictive biomarkers for immunotherapy response and their role in bladder cancer. *International immunopharmacology*, 152, 114381.

Xiong W, et al. (2025) Short-term high-dose gemcitabine induces PERK-mediated immunogenic cell death and potentiates antitumor immunity in bladder cancer. *International immunopharmacology*, 162, 115057.

Ling Z, et al. (2025) Stem Cell-Related Gene CALR as a Novel Prognostic Factor for Bladder Cancer: Implications for Immunotherapy. *Human mutation*, 2025, 5569005.

Zhang J, et al. (2025) Prostate Cancer Cells Secrete PD-1 in Exosomes to Enhance Myeloid-Derived Suppressor Cell Activity and Promote Tumor Immune Evasion. *Cancer research*, 85(18), 3435.

Okholm TLH, et al. (2024) circHIPK3 nucleates IGF2BP2 and functions as a competing endogenous RNA. *eLife*, 13.

Kawahara I, et al. (2024) Targeting metabolic reprogramming to overcome drug resistance in advanced bladder cancer: insights from gemcitabine- and cisplatin-resistant models. *Molecular oncology*, 18(9), 2196.

Mann J, et al. (2024) Combined inhibition of RAD51 and CHK1 causes synergistic toxicity in cisplatin resistant cancer cells by triggering replication fork collapse. *International*

journal of cancer.

Dodson AE, et al. (2024) Pan-Cancer Analysis of Homologous Recombination Deficiency in Cell Lines. *Cancer research communications*, 4(12), 3084.

Graham K, et al. (2024) Discovery of YAP1/TAZ pathway inhibitors through phenotypic screening with potent anti-tumor activity via blockade of Rho-GTPase signaling. *Cell chemical biology*, 31(7), 1247.

Yan Y, et al. (2024) IMP2 drives chemoresistance by repressing cisplatin-induced apoptosis and ferroptosis via activation of IPO4 and SLC7A11 under hypoxia in bladder cancer. *Cancer cell international*, 24(1), 386.